Immunogen, Inc.

Imclone LLC

Hans K Erickson

Ravi V J Chari

Viktor S Goldmakher

Robert J Lutz

Yelena V Kovtun

Rita M Steeves

John M Lambert

Gregory D Plowman

Wayne Charles Widdison

Dale Lincoln Ludwig

Paul J Balderes

Alan C Rigby

Scott W Eastman

Christopher M Moxham

The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.

Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment

Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.

Elimination of heterogeneous or mixed cell population in tumors

Growing community of inventors

Belmont, MA, United States of America

Hans K Erickson